Curis, Inc.  

(Public, NASDAQ:CRIS)   Watch this stock  
Find more results for CRIS
2.91
-0.17 (-5.52%)
After Hours: 2.91 0.00 (0.00%)
Dec 9, 4:30PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.90 - 3.08
52 week 1.25 - 3.72
Open 3.06
Vol / Avg. 539,449.00/607,268.00
Mkt cap 428.47M
P/E     -
Div/yield     -
EPS -0.48
Shares 140.55M
Beta 1.88
Inst. own 50%
Feb 27, 2017
Q4 2016 Curis Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 3, 2016
Q3 2016 Curis Inc Earnings Release
Nov 3, 2016
Q3 2016 Curis Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -1611.43% -748.64%
Operating margin -1579.82% -716.91%
EBITD margin - -714.87%
Return on average assets -162.07% -74.86%
Return on average equity -270.51% -125.10%
Employees 44 -
CDP Score - -

Address

4 Maguire Rd
LEXINGTON, MA 02421-3112
United States - Map
+1-617-5036500 (Phone)
+1-617-5036501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company's drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.

Officers and directors

James R. McNab Jr. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Ali Fattaey Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
James E. Dentzer Chief Financial Officer, Chief Administrative Officer, Treasurer, Secretary
Age: 49
Bio & Compensation  - Reuters
Mani Mohindru Ph.D. Senior Vice President, Chief Strategy Officer
Bio & Compensation  - Reuters
David Tuck M.D. Senior Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Lori A. Kunkel M.D. Director
Age: 66
Bio & Compensation  - Reuters
Kenneth J. Pienta M.D. Director
Age: 55
Bio & Compensation  - Reuters
Martyn D. Greenacre Independent Director
Age: 73
Bio & Compensation  - Reuters
Kenneth I. Kaitin Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Robert E. Martell M.D., Ph.D. Independent Director
Age: 52
Bio & Compensation  - Reuters